Vistagen Therapeutics Inc (VTGN) Price Prediction & ForecastVTGNVistagen Therapeutics Inc

Alphio's VTGN stock price prediction model matches the current Vistagen Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.16 (-2.98%). The 1-week path is $0.15 (-6.63%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Vistagen Therapeutics is not a good buy right now due to its current price of $0.1645, which is near its 52-week low of $0.16, and a troubling RSI of 32.407 indicating oversold conditions. The company has experienced a staggering 95.87% decline over the past year, and despite a revenue surge to $1.27 million, it reported a net loss of $13 million in the last quarter, reflecting ongoing financial struggles. The main risk is the failure of its drug trial, which caused a 71% drop in stock price, highlighting significant volatility and uncertainty.

Vistagen Therapeutics Inc (VTGN) last closed at $0.1645, losing -0.42%. These facts feed the 1-day and 1-week VTGN price prediction above.